Literature DB >> 21718986

Functional and anatomic results after creation of a neovagina according to Wharton-Sheares-George in patients with Mayer-Rokitansky-Küster-Hauser syndrome-long-term follow-up.

Katharina Walch1, Eleen Kowarik, Katharina Leithner, Theresa Schätz, Daniela Dörfler, René Wenzl.   

Abstract

OBJECTIVE: To evaluate the long-term outcomes and degree of satisfaction after neovaginoplasty according to Wharton-Sheares-George in women with Mayer-Rokitansky-Küster-Hauser syndrome.
DESIGN: Open, monocentric follow-up study.
SETTING: University hospital and referral center for pediatric and adolescent gynecology. PATIENT(S): Ten patients with Mayer-Rokitansky-Küster-Hauser syndrome with neovaginas created according to Wharton-Sheares-George 3 to 77 months ago. INTERVENTION(S): Gynecologic follow-up examination, including vaginal swab, bacterial culture, Papanicolaou smear, hybrid capture test for human papillomavirus typing, biopsy, pelvic ultrasound, and 2 questionnaires concerning global quality of life and degree of sexual satisfaction. MAIN OUTCOME MEASURE(S): Satisfaction with sexual function, quality of life, length and width of neovagina, structure of vaginal epithelium, and type of bacterial colonization. RESULT(S): Functional long-term follow-up results showed a high subjective degree of general well-being and sexual satisfaction in affected women. A satisfactory neovaginal length (mean, 8.3 ± 1.06 cm; range, 7-10 cm) and width (mean, 3.3 ± 0.5 cm; range, 2.5-4 cm) was obtained. As revealed by smears and biopsy, the neovagina resembled a natural vagina with regard to type of bacterial colonization and structure of epithelium. CONCLUSION(S): The goal of any method of creating a neovagina is to provide the patient the possibility to have satisfactory sexual intercourse and to enhance well-being and quality of life. These aims can be achieved by creating a neovagina according to Wharton-Sheares-George.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21718986     DOI: 10.1016/j.fertnstert.2011.06.004

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

Review 1.  Dilation and surgical management in vaginal agenesis: a systematic review.

Authors:  Sarah K McQuillan; Sonia R Grover
Journal:  Int Urogynecol J       Date:  2013-10-10       Impact factor: 2.894

2.  Prolapse and sexual function 8 years after neovagina according to Shears: a study of 43 cases with Mayer-von Rokitansky-Küster-Hauser syndrome.

Authors:  Annette Kuhn; Corinne Neukomm; Ekkehard F Dreher; Jeannine Imobersteg; Michael D Mueller
Journal:  Int Urogynecol J       Date:  2012-11-16       Impact factor: 2.894

3.  Sexual satisfaction in patients with Mayer-Rokitansky-Küster-Hauser syndrome after surgical and non-surgical techniques: a systematic review.

Authors:  Sahar Dabaghi; Mitra Zandi; Mahnaz Ilkhani
Journal:  Int Urogynecol J       Date:  2019-01-05       Impact factor: 2.894

4.  Sexual and Psychosocial Functioning in Women with MRKHS after Neovaginoplasty According to Wharton-Sheares-George: A Case Control Study.

Authors:  Katharina Leithner; Andrea Naderer; Dorothee Hartung; Clara Abrahamowicz; Johanna Alexopoulos; Katharina Walch; René Wenzl; Eva Hilger
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

5.  Clinical pilot study to evaluate the neovaginal PACIENA prosthesis® for vaginoplasty without skin grafts in women with vaginal agenesis.

Authors:  Pedro Acién; Francisco J Nohales-Alfonso; Maria-Luisa Sánchez-Ferrer; Miguel Sánchez-Lozano; Victoria Navarro-Lillo; Maribel Acién
Journal:  BMC Womens Health       Date:  2019-11-26       Impact factor: 2.809

6.  Effects of different vaginal mould use approaches after vaginoplasty with artificial dermis in patients with Mayer-Rokitansky-Küster-Hauser syndrome.

Authors:  Wenli Wang; Fang Chen; Jiumei Cheng; Shuyan Peng; Hong Ye
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.